Simon et al. conducted a cohort study showing that GLP-1 RA use was associated with a lower risk of cirrhotic decompensation than DPP-4 inhibitors or sulfonylureas in patients with liver cirrhosis [26]. The gene discussed is GLP1R; the disease is cirrhosis of liver.